Koshinski Asset Management Inc. Raises Stake in Humana Inc. (NYSE:HUM)

Koshinski Asset Management Inc. boosted its position in Humana Inc. (NYSE:HUM) by 64.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,814 shares of the insurance provider’s stock after buying an additional 710 shares during the period. Koshinski Asset Management Inc.’s holdings in Humana were worth $706,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HUM. Baillie Gifford & Co. acquired a new position in Humana in the second quarter valued at approximately $26,000. Cordasco Financial Network acquired a new position in Humana in the second quarter valued at approximately $33,000. Credit Agricole S A acquired a new position in Humana in the second quarter valued at approximately $46,000. Sandy Spring Bank lifted its holdings in Humana by 126.6% in the second quarter. Sandy Spring Bank now owns 179 shares of the insurance provider’s stock valued at $79,000 after acquiring an additional 100 shares during the period. Finally, Parkside Financial Bank & Trust lifted its holdings in Humana by 14.3% in the second quarter. Parkside Financial Bank & Trust now owns 192 shares of the insurance provider’s stock valued at $85,000 after acquiring an additional 24 shares during the period. Hedge funds and other institutional investors own 91.75% of the company’s stock.

HUM stock opened at $436.19 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.72 and a quick ratio of 1.72. The firm has a market capitalization of $56.07 billion, a P/E ratio of 21.06, a P/E/G ratio of 1.58 and a beta of 0.94. The business’s 50-day moving average is $430.24 and its two-hundred day moving average is $431.95. Humana Inc. has a 1 year low of $370.22 and a 1 year high of $475.44.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 3rd. The insurance provider reported $4.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.61 by $0.22. The company had revenue of $20.70 billion for the quarter, compared to analyst estimates of $20.91 billion. Humana had a return on equity of 14.95% and a net margin of 3.30%. Humana’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter last year, the company earned $3.08 EPS. On average, analysts expect that Humana Inc. will post 20.54 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, January 28th. Shareholders of record on Friday, December 31st will be given a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date is Thursday, December 30th. Humana’s dividend payout ratio is currently 13.52%.

In related news, CEO Bruce D. Broussard sold 50,006 shares of the firm’s stock in a transaction that occurred on Friday, November 5th. The stock was sold at an average price of $454.70, for a total transaction of $22,737,728.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director David A. Jr/Ky Jones sold 4,800 shares of Humana stock in a transaction that occurred on Thursday, September 16th. The shares were sold at an average price of $401.00, for a total value of $1,924,800.00. The disclosure for this sale can be found here. 0.40% of the stock is owned by company insiders.

A number of research analysts have issued reports on the company. Oppenheimer boosted their price target on Humana from $480.00 to $510.00 and gave the company an “outperform” rating in a report on Thursday, November 4th. SVB Leerink increased their price objective on Humana from $494.00 to $528.00 and gave the company an “outperform” rating in a research note on Thursday, November 4th. Bank of America upped their target price on Humana from $505.00 to $530.00 and gave the company a “buy” rating in a report on Thursday, November 4th. Barclays upped their target price on Humana from $500.00 to $540.00 and gave the company an “overweight” rating in a report on Thursday, November 4th. Finally, Morgan Stanley increased their price target on Humana from $513.00 to $559.00 and gave the stock an “overweight” rating in a report on Thursday, November 4th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $503.51.

About Humana

Humana Inc engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental benefit plans such as Medicare, and State-based Medicaid contracts.

Featured Story: Bear Market

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.